Premium
Bortezomib and heart failure: case‐report and review of the French P harmacovigilance database
Author(s) -
Honton Benjamin,
Despas Fabien,
Dumonteil Nicolas,
Rouvellat Caroline,
Roussel Murielle,
Carrie Didier,
Galinier Michel,
Montastruc Jean Louis,
Pathak Atul
Publication year - 2014
Publication title -
fundamental and clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.655
H-Index - 73
eISSN - 1472-8206
pISSN - 0767-3981
DOI - 10.1111/fcp.12039
Subject(s) - bortezomib , multiple myeloma , medicine , heart failure , proteasome inhibitor , drug reaction , adverse effect , drug , lymphoma , cardiology , oncology , pharmacology
Bortezomib is a proteasome inhibitor commonly indicated for the treatment of multiple myeloma and non H odgkin lymphoma. Cardiac adverse drug reactions of this drug are not clearly established. We report case where direct involvement of bortezomib in the occurrence of heart failure is strongly suspected and 22 other cases spontaneously reported to the F rench P harmacovigilance S ystem. This report should increase cardiologist awareness about the risk of heart failure related to this drug. Moreover, these cases underline the need for a systematic cardiac screening in patients exposed to bortezomib.